How Ozempic's maker lost its grip on the obesity market it created
Today, the Danish company has lost its grip on the anti-obesity market it carved out.
The company has lost market share amid production missteps and a bungled rollout of Wegovy that led to shortages. Its U.S. rival Eli Lilly—initially in the rearview mirror—has been proven to have the more effective weight-loss drug and a more promising pipeline of next-generation treatments. Novo Nordisk's research-and-development machine has disappointed, and a key marketing strategy was slow to get off the ground.
Novo Nordisk's ability to stay atop a market that analysts see growing to $150 billion in annual sales is now in doubt. Its controlling shareholder this month forced a surprise ouster of the company's chief executive, Lars Fruergaard Jørgensen. And while it is still generating multibillion-dollar sales for Ozempic and Wegovy, shares have tumbled more than 50% over the past year.
If Novo Nordisk doesn't turn things around, it could join a long list of companies that blew a first-mover advantage, from Sunshine Biscuits—whose Hydrox cookies were overtaken by now-iconic Oreos—to the Myspace social network.
'Everyone wants to be the first footprints on the empty beach," said Americus Reed, marketing professor at the Wharton School of the University of Pennsylvania. 'But it depends on how you land on that first move. The second mover is watching them make mistakes. You're able to identify those and not make those mistakes."
Lars Fruergaard Jørgensen, who was pushed out as CEO of Novo Nordisk earlier this month.Novo Nordisk lost market share after miscalculating demand in the launch of weight-loss drug Wegovy.
A Novo Nordisk spokeswoman said the company remains the global-volume market leader in GLP-1 drugs, serving nearly two-thirds of patients taking them for diabetes and obesity.
Some investors and industry watchers say Novo Nordisk's troubles stem from a cautious, reactive approach starting when the market first burst onto the scene, in contrast with a faster, more aggressive tack in production and marketing by Lilly.
'Novo is always a step behind," said Yuri Khodjamirian, chief investment officer at Tema ETFs, which owns Novo Nordisk shares.
One of Novo Nordisk's early stumbles was underestimating the demand for Wegovy—the weight-loss version of semaglutide, the same compound as diabetes drug Ozempic—ahead of its 2021 launch. The company's planning was informed by its experience generating modest sales for an earlier weight-loss drug, Saxenda. Doctors were skeptical of it, and many health-insurance plans in the U.S. didn't cover weight-loss drugs.
Novo Nordisk thought Wegovy might run into the same market constraints as Saxenda, so the company planned modest production levels, using a combination of in-house and contract manufacturing capacity.
It wasn't enough. It took only five weeks for the prescription rate of Wegovy to exceed the level that Saxenda had taken five years to reach. Jørgensen recalled later, in an interview in 2024, that he initially thought: ''That's patients who've been lined up, there's pent-up demand, it will normalize.' It didn't. It just kept growing."
The company responded by limiting demand—the last thing a drugmaker wants to do with a new product. Sales representatives asked doctors not to start new patients. The company resorted to rationing by withholding the lower, starter doses for new patients, to conserve supplies for existing patients taking the higher doses.
The shortages opened the door for competition. They made it legal for special pharmacies in the U.S. to make compounded, copycat versions of semaglutide that sold for much less than list prices for Ozempic and Wegovy. Telehealth firms capitalized on the new, lower-cost supply by hawking the compounded versions, taking away market share from Novo Nordisk.
Eli Lilly activated a manufacturing plant in Concord, N.C., to keep up with a surge in demand for Mounjaro and Zepbound.
The shortages gave rival Eli Lilly time to catch up. Lilly introduced Mounjaro for diabetes in 2022, followed by Zepbound, a weight-loss version of the same drug, in 2023. Zepbound has been shown in studies to induce greater weight loss than Wegovy, more than 20% of body weight.
Although Lilly also encountered shortages due to high demand, it was able to resolve them more quickly than Novo Nordisk. Now, weekly U.S. prescriptions for Lilly's Zepbound have surpassed Wegovy's. Mounjaro still trails Ozempic but is closing the gap.
Novo Nordisk has spent billions of dollars trying to expand manufacturing capacity, including an unusual deal last year for its controlling foundation to acquire the contract manufacturer Catalent for $16 billion.
The R&D race for future weight-loss drugs also has tilted in Eli Lilly's direction. Lilly has reported favorable clinical-trial data for two closely watched experimental drugs, including a pill version that analysts think could be appealing to people who don't want injections.
Novo Nordisk, meanwhile, has had some R&D disappointments, including studies of an experimental combination weight-loss drug dubbed CagriSema. The less-than-expected results of one study sent Novo Nordisk shares plunging more than 20% in one day in December, wiping out nearly $100 billion in stock-market capitalization for the company. Some analysts have cut their sales forecasts for the drug.
Novo Nordisk's Wegovy has been surpassed in weekly U.S. prescriptions by Lilly's Zepbound.
Lilly has gained an edge on the marketing front as well. The company beat Novo Nordisk to the punch in launching a direct-to-consumer, online service selling weight-loss drugs at discounted cash prices, aimed at people who don't have insurance coverage. And it was first to strike a deal with a big telehealth firm, Ro, to sell a discounted weight-loss drug. Novo Nordisk eventually made similar moves, but months after Lilly.
'They seem to be missing a lot of these kinds of strategic endeavors to help sell into a market that is different from a lot of pharma markets," said BMO Capital Markets analyst Evan David Seigerman.
The Novo Nordisk spokeswoman said the company resolved its shortages before announcing its direct-to-patient service and striking telehealth deals.
Novo Nordisk isn't out of the race. The company can still turn things around by leaning into CagriSema, which generated solid weight-loss data even if it missed expectations, and by developing other new drugs that target various segments of the growing market, Seigerman said.
More recently, Novo Nordisk has shown signs of being more aggressive. It signed a deal with CVS to make Wegovy the preferred weight-loss drug for members of its drug-benefit plans.
Author Hanne Sindbæk, who has written two books about Novo Nordisk, says there has been an eternal tug of war inside the company between those who are guided by values—the idea that the company works for the common good rather than simply to make a profit—and those who run the business. If Novo Nordisk wants to stay in the game, it may have to lean toward the latter in choosing its next CEO.
Jørgensen, the outgoing CEO, is still in his role while the company searches for a new chief. His predecessor as CEO, Lars Rebien Sørensen, who is chairman of the foundation that has voting control of the drugmaker's shares, will join the Novo Nordisk board of directors.
'Now they need somebody more business-driven," Sindbæk said.
Write to Peter Loftus at Peter.Loftus@wsj.com and Noemie Bisserbe at noemie.bisserbe@wsj.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
27 minutes ago
- Time of India
US targets knockoff weight-loss drugs
Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. On Friday, a group of more than 80 bipartisan lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market—a problem that emerged over the last year. 'We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications,' they wrote in a letter to FDA commissioner Marty Makary. 'Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences.' The group—spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey—asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the 'urgency' of the situation. A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a 'complete and thorough' response to the issues raised in the lawmakers' letter. 'Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously,' the spokesperson said. 'And we are deeply committed to strengthening the oversight of imported products at US ports of entry.' In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalise on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage but are no longer permitted to do so after Novo Nordisk and Eli Lilly boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalisations potentially linked to the copycat drugs, but that adverse events are likely being underreported. 'We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs,' said a spokesperson for Hims & Hers Health , one of the telehealth firms that sells compounded GLP-1s. 'We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first.' Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments.
Hindustan Times
an hour ago
- Hindustan Times
Luxury Brands Are Getting Hit by a Vibe Shift
Is the luxury industry going through a short-term blip or something more serious? Bernard Arnault, the billionaire owner of Louis Vuitton and more than 70 other luxury brands, says the current sales slump will blow over. If he is right, now is the time to buy LVMH stock, which is down a fifth so far this year. He has spent more than $1 billion of his own cash on the company's shares since January. But investors are concerned that something is amiss. UBS analysts covering Europe's top luxury stocks said that after two years of waiting for a recovery, 'investors are starting to worry about the long-term structural attractiveness of the industry.' LVMH reported results last week and said sales at its fashion and leather goods division fell 9% from a year earlier in the second quarter, which was worse than expected. The unit is the company's main cash cow and generated nearly 80% of the group's operating profit in 2024. Management blamed weak demand for brands such as Louis Vuitton and Christian Dior on lower tourist spending. This time last year, the Chinese were snapping up luxury goods in Japan as a weak yen meant bargains were available. But that arbitrage window has closed. Moncler, which reported flattish results earlier in the week, flagged the same issue. Consumers might simply be digesting everything they bought in a record luxury binge during the pandemic. But something feels off. This year, sales across the luxury industry are expected to be flat, Bernstein estimates. That is unusual because the industry normally grows at twice the rate of global economic growth and this will be the second consecutive year of lackluster demand: 2024 was the sector's worst performance since the 2008 global financial crisis—even though there wasn't a recession. There is no clear sign in the data that large luxury brands are losing significant market share to smaller insurgent brands such as handbag maker Polene, according to consulting firm Bain & Company. But certain types of luxury goods are out of fashion. Handbag prices went off the rails during the pandemic and shoppers have diverted their spending to categories they think offer better value for money. Jewelry brands, which didn't raise prices as aggressively over the past four years, are still reporting healthy growth. Cartier owner Richemont said sales of its jewelry division rose 11% in the three months through June compared with a year ago. Demand for Richemont's lower-priced products is still strong, an indication that aspirational shoppers who have deserted brands like Gucci are still showing up at Cartier. Luxury brands also seem to have a problem on their hands with younger consumers. Last year, sales to Gen Z shoppers fell 7%, equivalent to a $5.7 billion drop in spending and the sharpest pullback among all generations. They appear disillusioned with luxury goods after stories about abuses in the industry's supply chain and extreme price markups went viral on social media. People are tuning out online. Growth in the number of people who follow luxury brands on social media is flatlining and online engagement in 2025 is only 40% what was recorded in 2022, Bain notes. The number of vintage dresses appearing on red carpets is a sign of a shift. As luxury brands have become oversaturated on social media, access to rare, one-off pieces is becoming more of a status symbol than shelling out thousands of dollars on the latest handbag. Luxury companies have been here before. In 2015, consumers grew tired of logos and brands were forced to pivot. New, discrete designs like the Louis Vuitton Capucines successfully got people spending again. Multibillion-dollar ad budgets make the biggest luxury companies formidable players. And a wave of innovation is on the way: At least a dozen major luxury brands, including Chanel, Gucci and Dior, have new creative designers who will be showing fresh collections later this year. But the industry is 50% bigger today than it was a decade ago. Even if the latest crop of designers nail what young customers want, it will be tougher for mature brands to grow at the clip that shareholders have become accustomed to. Write to Carol Ryan at
Time of India
3 hours ago
- Time of India
European shares rise to 4-month high after US-EU trade deal
Synopsis European shares surged to a four-month high following the EU-U.S. trade deal, which averted a wider trade war. Auto and pharmaceutical stocks led the gains, with Porsche, Volkswagen, Novo Nordisk and Roche rising significantly. The STOXX 600 index is now within 1.8% of its all-time high, fueled by expectations of further trade agreements.
